EXAS vs NCDL · rev $2.76B vs P/E 8.9, $837.2M cap
EXACT Sciences Corporation (EXAS) versus Nuveen Churchill Direct Lending Corp. (NCDL) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Nuveen Churchill Direct Lending Corp. (NCDL) is a asset management company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
NCDL does not have a complete income-statement cache yet.
EXAS currently screens at market cap $20.03B. NCDL currently screens at market cap $837.2M and trailing P/E 8.9.
Not investment advice. Open the EXAS and NCDL stock pages for the full models.
Not investment advice.